ArticleInternational urology and nephrology2026
Institutional adherence, complication rates, and intravesical recurrence with intraoperative mitomycin C during radical nephroureterectomy.
Article in International urology and nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeWe evaluated institutional adherence, complication rates, and intravesical recurrence (iVR) with intraoperative intravesical mitomycin C (MMC) instillation immediately after bladder cuff closure during radical nephroureterectomy (RNU) for upper urinary tract urothelial carcinoma (UTUC).
methodsThis retrospective single-centre study included patients with UTUC who underwent RNU at Zealand University Hospital (2017-2023). The primary endpoint was adherence to the intraoperative intravesical MMC protocol following its implementation in 2018. Secondary endpoints were 90-day postoperative complications (Clavien-Dindo classification [CDC]) and iVR within 24 months. Cumulative incidence functions accounted for death as a competing event, and multivariable Fine-Gray regression was performed.
resultsAmong 140 patients who underwent RNU, 101 received intraoperative intravesical MMC while one received it postoperatively. The institutional adherence cohort comprised 116 patients treated after protocol implementation, of whom 99 (85.3%) received MMC. Among the 17 who did not, reasons were bladder leakage (8, 47.1%), previous bladder cancer (3, 17.6%), and undocumented rationale (6, 35.3%). Major postoperative complications (CDC ≥ III) did not differ significantly between groups (9.8% MMC vs 7.9% no-MMC, p = 1.0). The 24-month cumulative incidence of iVR was lower with MMC (25.0% vs 45.0%; p = 0.013). In multivariable competing-risk analysis, MMC remained independently associated with reduced iVR (subdistribution hazard ratio 0.40, 95% CI 0.20-0.78).
conclusionIntraoperative MMC instillation after bladder cuff closure achieved high institutional adherence with no significant increase in major postoperative complications and achieved a low 24-month incidence of iVR. As the comparison group was non-contemporaneous, the oncological findings are exploratory.
Indexed as
Identifiers
42853326What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.